Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

FRET imaging and statistical signal processing reveal positive and negative feedback loops regulating the morphology of randomly migrating HT-1080 cells

(2012) K. Kunida et al.   JOURNAL OF CELL SCIENCE

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Anticancer Activity of Metal Complexes: Involvement of Redox Processes

(2011) Ute Jungwirth et al.   ANTIOXIDANTS & REDOX SIGNALING

Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer

(2011) Alberto J. Montero et al.   DRUGS

4-Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling

(2011) Huang-Hui Chen et al.   FREE RADICAL BIOLOGY AND MEDICINE

Mechanism of p53 stabilization by ATM after DNA damage

(2010) Qian Cheng et al.   CELL CYCLE

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

(2010) Dina Ali et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

(2010) K G Wiman   ONCOGENE

Efficient, high-throughput transfection of human embryonic stem cells

(2010) Jennifer C Moore et al.   Stem Cell Research & Therapy

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells

(2009) M. Miyachi et al.   CLINICAL CANCER RESEARCH

TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

(2009) M Jasek et al.   LEUKEMIA

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology